IR Biosciences Holdings (OTCPK:IRBS) - Stock Price, News & Analysis

IRBS Stock Overview

IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. More details

IRBS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($17)

Latest financial reports are more than a year old

Shares are highly illiquid

IR Biosciences Holdings, Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Price History & Performance

Summary of all time highs, changes and price drops for IR Biosciences Holdings
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	0%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IRBS	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how IRBS performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IRBS performed against the US Market.

Price Volatility

Is IRBS's price volatile compared to industry and market?
IRBS volatility
IRBS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IRBS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IRBS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	n/a	n/a

IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing.

IR Biosciences Holdings, Inc. Fundamentals Summary

How do IR Biosciences Holdings's earnings and revenue compare to its market cap?
IRBS fundamental statistics
Market cap	US$17.00
Earnings (TTM)	-US$5.41m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is IRBS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IRBS income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$5.41m
Earnings	-US$5.41m

Last Reported Earnings

Dec 31, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did IRBS perform over the long term?

See historical performance and comparison